The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- p-glucagon
研究概览
简要总结
The overall objective of this study is to investigate whether hypoglycaemia (the most potent stimulus of pancreatic glucagon secretion) affects the secretion of gut-derived glucagon in totally pancreatectomized patients.
详细描述
The investigators want to assess the plasma glucagon response to insulin-induced hypoglycaemia in totally pancreatectomised patients and at the same time evaluate whether hypoglycaemia affects a range of other products from endocrine cells in the gastrointestinal tract including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic polypeptide (GIP), GLP-1, glucagon-like peptide-2 (GLP-2), oxyntomodulin and peptide YY (PYY). Furthermore the investigators will evaluate how hypoglycaemia in these patients affects other counter-regulatory mechanisms including plasma responses of the hormones adrenaline, noradrenaline, growth hormone and cortisol as well as the rate of gastric emptying rate (which under normal circumstances accelerates during hypoglycaemia) during an oral glucose tolerance test (OGTT).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Pancreatectomised patients
- •Caucasian above 30 years of age who have undergone total pancreatectomy
- •Blood haemoglobin >7.0 mmol/l for males and >6.5 mmol/l for females Non-diabetic control subjects
- •Normal fasting plasma glucose and normal HbA1c (according to the World Health Organization (WHO) criteria)
- •Normal blood haemoglobin
- •Caucasian above 30 years of age
- •BMI (body mass index) 17-30
- •Informed consent
排除标准
- •Pancreatectomised patients
- •Pancreatectomy within the last 3 months
- •Ongoing chemotherapy or chemotherapy within the last 3 months
- •Previous or ongoing treatment with GLP-1 receptor agonists or dipeptidyl peptidase 4 (DPP-4) inhibitors
- •Inflammatory bowel disease
- •Gastrointestinal resection (other than the gastro-duodenectomy performed in connection with total pancreatectomy) and/or ostomy
- •Nephropathy (eGFR<60 and/or albuminuria)
- •Known liver disease (excluding non-alcoholic fatty liver disease) and/or serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >3 × normal values)
- •Severe lung disease
- •Pregnancy and/or breastfeeding
- •Age above 85 years
- •Uncontrolled hypertension and/or significant cardiovascular disease
- •Any condition that the investigator feels would interfere with trial participation Non-diabetic control subjects
- •Diabetes or prediabetes (according to WHO criteria)
- •First-degree relatives with diabetes
- •Inflammatory bowel disease
- •Gastrointestinal resection and/or ostomy
- •Nephropathy (serum creatinine >150 µmol/l and/or albuminuria)
- •Known liver disease (excluding non-alcoholic fatty liver disease) and/or serum ALAT and/or serum ASAT >3 × normal values)
- •Severe lung disease
- •Pregnancy and/or breastfeeding
- •Age above 85 years
- •Uncontrolled hypertension and/or significant cardiovascular disease
- •Any condition that the investigator feels would interfere with trial participation
研究组 & 干预措施
Healthy controls
Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
干预措施: Oral glucose tolerance test (Other)
Totally pancreatectomized patients
Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
干预措施: Oral glucose tolerance test (Other)
Totally pancreatectomized patients
Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
干预措施: Clamp experiment (Other)
Healthy controls
Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
干预措施: Clamp experiment (Other)
结局指标
主要结局
p-glucagon
时间窗: -30, -15, 0, 15, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210, 240 minutes
Plasma glucagon excursions measured as incremental area under the curve (iAUC)
次要结局
- catecholamines(-30, -15, 0, 15, 40, 50, 60, 70, 80, 90 minutes)
- p-glucose(-30, -15, 0, 15, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210, 240 minutes)
- GIP, GLP-1, GLP-2, GIP, oxyntomodulin, ghrelin, peptide YY, gastrin(-30, -15, 0, 15, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210, 240 minutes)
- cortisol(-30, -15, 0, 15, 40, 50, 60, 70, 80, 90 minutes)
- growth hormone(-30, -15, 0, 15, 40, 50, 60, 70, 80, 90 minutes)
研究者
Filip Krag Knop
Consultant endocrinologist, Professor of
University Hospital, Gentofte, Copenhagen